Fan S, Lai K
Medicine (Baltimore). 2025; 103(52):e41080.
PMID: 39969314
PMC: 11687997.
DOI: 10.1097/MD.0000000000041080.
Knaneh J, Hodak E, Fedida-Metula S, Edri A, Eren R, Yoffe Y
Cancers (Basel). 2023; 15(17).
PMID: 37686697
PMC: 10486495.
DOI: 10.3390/cancers15174421.
Fay C, Awh K, LeBoeuf N, Larocca C
Front Oncol. 2023; 12:1071171.
PMID: 36713518
PMC: 9878398.
DOI: 10.3389/fonc.2022.1071171.
Hristov A, Tejasvi T, Wilcox R
Am J Hematol. 2022; 98(1):193-209.
PMID: 36226409
PMC: 9772153.
DOI: 10.1002/ajh.26760.
Vermeer M, Moins-Teisserenc H, Bagot M, Quaglino P, Whittaker S
Br J Dermatol. 2022; 187(1):21-28.
PMID: 35157307
PMC: 9541328.
DOI: 10.1111/bjd.21053.
Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas.
Sugaya M
Int J Mol Sci. 2021; 22(20).
PMID: 34681738
PMC: 8537763.
DOI: 10.3390/ijms222011079.
Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
Hristov A, Tejasvi T, Wilcox R
Am J Hematol. 2021; 96(10):1313-1328.
PMID: 34297414
PMC: 8486344.
DOI: 10.1002/ajh.26299.
Novel targeted therapies of T cell lymphomas.
Izykowska K, Rassek K, Korsak D, Przybylski G
J Hematol Oncol. 2021; 13(1):176.
PMID: 33384022
PMC: 7775630.
DOI: 10.1186/s13045-020-01006-w.
The importance of assessing blood tumour burden in cutaneous T-cell lymphoma.
Vermeer M, Nicolay J, Scarisbrick J, Zinzani P
Br J Dermatol. 2020; 185(1):19-25.
PMID: 33155285
PMC: 8359272.
DOI: 10.1111/bjd.19669.
Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.
Oka T, Miyagaki T
Front Med (Lausanne). 2019; 6:116.
PMID: 31192214
PMC: 6548851.
DOI: 10.3389/fmed.2019.00116.
Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma.
Dulmage B, Akilov O, Vu J, Falo L, Geskin L
Oncotarget. 2019; 10(33):3104-3113.
PMID: 31139323
PMC: 6517103.
DOI: 10.18632/oncotarget.5742.
Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression.
Borcherding N, Voigt A, Liu V, Link B, Zhang W, Jabbari A
Clin Cancer Res. 2019; 25(10):2996-3005.
PMID: 30718356
PMC: 6659117.
DOI: 10.1158/1078-0432.CCR-18-3309.
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.
Prieto-Torres L, Rodriguez-Pinilla S, Onaindia A, Ara M, Requena L, Piris M
Haematologica. 2019; 104(2):226-235.
PMID: 30630983
PMC: 6355473.
DOI: 10.3324/haematol.2018.197152.
New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.
Fujii K
Front Oncol. 2018; 8:198.
PMID: 29915722
PMC: 5994426.
DOI: 10.3389/fonc.2018.00198.
Activating and inhibitory receptors on natural killer cells in patients with systemic lupus erythematosis-regulation with interleukin-15.
Lin S, Kuo M, Hsiao H, Lee P, Chen J, Huang J
PLoS One. 2017; 12(10):e0186223.
PMID: 29023581
PMC: 5638402.
DOI: 10.1371/journal.pone.0186223.
Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.
Schmitt C, Marie-Cardine A, Bensussan A
Front Immunol. 2017; 8:1010.
PMID: 28912774
PMC: 5582066.
DOI: 10.3389/fimmu.2017.01010.
New Targeted Treatments for Cutaneous T-cell Lymphomas.
Bagot M
Indian J Dermatol. 2017; 62(2):142-145.
PMID: 28400633
PMC: 5363137.
DOI: 10.4103/ijd.IJD_73_17.
The biomarker landscape in mycosis fungoides and Sézary syndrome.
Dulmage B, Geskin L, Guitart J, Akilov O
Exp Dermatol. 2016; 26(8):668-676.
PMID: 27897325
PMC: 5489366.
DOI: 10.1111/exd.13261.
CD164 identifies CD4 T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.
Benoit B, Jariwala N, OConnor G, Oetjen L, Whelan T, Werth A
Arch Dermatol Res. 2016; 309(1):11-19.
PMID: 27766406
PMC: 5357118.
DOI: 10.1007/s00403-016-1698-8.
Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
Wilcox R
Am J Hematol. 2015; 91(1):151-65.
PMID: 26607183
PMC: 4715621.
DOI: 10.1002/ajh.24233.